Language
We detect your regional language is French. Do you want to change site's language to French? You may choose other languages.International
English
中文
русск
français
español
العربية
User Center
My Training Class
Feedback
With PARP inhibitor for treating Small Cell Lung Cancer
With PARP inhibitor for treating Small Cell Lung Cancer
This document describes the methods with poly- (ADP- ribose) polymerase (PARP) inhibitor or the Small Cell Lung Cancer subject of its pharmaceutically acceptable salt treatment expression Schlafen-11 (SLFN11).Specifically, the method includes detecting SLFN 11 in the tumor cells specimens from the subject, and a effective amount of PARP inhibitor, the toluene fulfonate of such as talazoparib or talazoparib are applied to the subject.
Original Text (This is the original text for your reference.)
This document describes the methods with poly- (ADP- ribose) polymerase (PARP) inhibitor or the Small Cell Lung Cancer subject of its pharmaceutically acceptable salt treatment expression Schlafen-11 (SLFN11).Specifically, the method includes detecting SLFN 11 in the tumor cells specimens from the subject, and a effective amount of PARP inhibitor, the toluene fulfonate of such as talazoparib or talazoparib are applied to the subject.
Inventor: EVELYN WANG;EVELYN WANG;KAREN YU;KAREN YU;LEONARD E. POST;LEONARD E POST;YING FENG;YING FENG;YUANBIN RU;YUANBIN RU;YUQIAO SHEN;YUQIAO SHEN
Application number: BR112018008503
Publication number: BR112018008503A2
Filing date: 2016-10-26
Publication date: 2020-05-26
Type of Patent: A2
Source: IKCEST
Translate engine
Article's language
Action
Report
Share
Related
Report
Select your report category*
Reason*
